LICENSE CATEGORIES
AVAILABLE LICENSES
LICENSE INFORMATION
  • Agriculture & Veterinary Medicine
    • A Natural Source Red Pigment

      A Natural Source Red Pigment

      A natural source red pigment with strong and stable color. The pigment appears unique and suitable for food and cosmetic industry use.

    Agriculture & Veterinary Medicine

  • Energy, Cleantech & Environmental

    Energy, Cleantech & Environmental

  • Engineering & Physical Sciences

    Engineering & Physical Sciences

  • Laboratory Research Tools & Reagents
    • Antibodies
      • CDF-4 Anti-Golgin Antibodies

        CDF-4 Anti-Golgin Antibodies

        The Golgi complex is composed of a stack of membrane-bound cisternae located in the cytoplasm adjacent to the nucleus.  The Golgi processes newly synthesized proteins (post-translational modification), sorts and routes them to their final destination.  At the outer surface of this complex or trans Golgi, vesicles containing modified proteins leave the Golgi.

        Researchers at the University of Calgary have developed and tested a monoclonal antibody that detects a component of the “trans” compartment of the Golgi apparatus.  This molecular biological tool can be used to detect the Golgi complex in a wide variety of cells including tissue culture cells such as HeLa cells, and HEp-2 cells, specialized cells (i.e. spermatids) and archived tissues. This antibody can be used as a reference marker in serological examination of patients diagnosed with Sjogren’s syndrome and other systemic autoimmune rheumatic diseases.  A large number of patients with anti-Golgi antibodies, particularly golgin97, have Sjogren’s syndrome.

      • EEA1 Monoclonal Antibodies

        EEA1 Monoclonal Antibodies

        Endocytosis is an important cellular process involved in many facets of cellular function, such as proliferative signaling, neuronal transmission, and the uptake of nutrients.  This process relies on the fusion of endocytic vesicles with early endosomes.  Early endosomes are responsible for sorting these events and recycling many of the plasma membrane associated receptors. The early endosomal antigen 1 (EEA1) protein, which is present on early endosomes, is involved in vesicle fusion during endocytosis.  In neurons, early endosomes are involved in recycling of neurotransmitter receptors, a necessary process in neuron to neuron signaling. Clinically, autoantibodies to EEA1 it have been detected in some patients with neurological deficits.  Moreover, autoantibodies to EEA1 were found to enhance excitatory synaptic transmission which may account, in part, for the neuropathies observed in patients with these autoantibodies.

        Researchers at the University of Calgary have developed and tested mouse monoclonal antibodies that specifically bind to the human EEA1 protein.  These antibodies can be utilized to detect the early endosomes by indirect immunofluorescence, immunohistochemistry, immunoprecipitation, and by Western blot analysis in both neuronal and non-neuronal cell types.

      • Monoclonal Antibodies Against Human MS4A4A

        Monoclonal Antibodies Against Human MS4A4A

      • Monoclonal Antibodies for Detection of GWBs

        Monoclonal Antibodies for Detection of GWBs

        GW bodies (GWBs, also known as mammalian P bodies) influence the expression and fate of mRNA, and thus the overall cellular mRNA profile. They are involved in the storage, transport and degradation of a subset of mRNA. GWBs are also linked to the RNA interference (RNAi) pathway resulting in either mRNA decay and/or translational repression.

        Researchers at the University of Calgary have developed mouse monoclonal antibodies that specifically bind the GW182 protein, a mRNA binding protein within GWBs. These antibodies can be utilized to detect the GW182 protein and GWBs by indirect immunofluorescence, immunohistochemistry, immunoprecipitation, and by Western blot analysis. These monoclonal antibodies can be used as reference markers to validate the presence of autoantibodies to GWBs in patients with motor/sensory neuropathy, Sjögren’s syndrome and systemic lupus erythematosus (SLE).

      • Monoclonal Antibodies to ING1 Isoforms

        Monoclonal Antibodies to ING1 Isoforms

        The ING genes encode a family of at least seven proteins with conserved plant homeodomain (PHD)-type zinc fingers in their C-termini. The founding member, ING1, is capable of binding to and affecting the activity of histone acetyltransferase (HAT), histone deacetylase (HDAC), and factor acetyltransferase (FAT) protein complexes. Upon UV irradiation, ING1 and ING2 bind stress induced signaling phospholipids such as phosphatidylinositol 5-monophosphate and cause cell cycle arrest.  ING1b interacts with proliferating cell nuclear antigen to promote DNA repair or induce apoptosis in cells to prevent tumorigenesis, depending upon the severity of DNA damage. ING proteins, which are down-regulated in a broad variety of cancer types, are able to restrict cell growth and proliferation, induce apoptosis, and modulate cell cycle progression, which strongly supports the notion that ING family proteins act as type II tumor suppressors.  The ING proteins regulate chromatin structure through specific binding to histones H3 and H4 via their plant homeodomains (PHDs) and recruitment of HAT & HDAC complexes to particular regions of chromatin, thus playing central roles in reading of the "histone code".

        Researchers at the University of Calgary have developed a panel of nine monoclonal antibodies (MAbs) against human and rodent ING1 proteins that specifically recognize the p33ING1b, p47ING1a and p24ING1c isoforms of ING1.

      • Monoclonal Antibody Against Human MS4A8B

        Monoclonal Antibody Against Human MS4A8B

      • Polyclonal Antibodies Against Human CD20

        Polyclonal Antibodies Against Human CD20

      Antibodies

    • Research Tools

      Research Tools

    • Cell Lines Expressing Calcium Channel and Genetically-Encoded Calcium Indicators

      Cell Lines Expressing Calcium Channel and Genetically-Encoded Calcium Indicators

      Voltage-gated calcium channels are important conduits for the entry of Ca2+ into numerous cell types, and consequently are major therapeutic targets for several disease states linked to ion channels. Conventional electrophysiological approaches used to study ion channels present many challenges that impede novel research and drug discoveries.

    • Novel Peptide Suppress Cava28 Subnit Function to Reduce Inflammatory and Neuropathic Pain

      Novel Peptide Suppress Cava28 Subnit Function to Reduce Inflammatory and Neuropathic Pain

      The global market for pain management is more than $7 billion annually, representing a huge opportunity for products which displace the use of opioids as a first line of treatment.

    Laboratory Research Tools & Reagents

  • Life & Medical Sciences
    • Diagnostics
      • A Serum-Based Diagnostic Test to Identify Pediatric Septic Shock

        A Serum-Based Diagnostic Test to Identify Pediatric Septic Shock

        Prompt detection of septic shock in pediatric patients thereby reducing the mortality rates of patients.

      • Novel Planar Microelectrodes with Unique Morphological Structure for Enhanced Neural Recording

        Novel Planar Microelectrodes with Unique Morphological Structure for Enhanced Neural Recording

      • PCR-based Diagnostic for Detection of Lyme Disease Bacteria

        PCR-based Diagnostic for Detection of Lyme Disease Bacteria

        Lyme disease is the most common tick-borne disease in North America, and is transmitted by blacklegged ticks carrying Borrelia bacteria.  Infection by a tick takes at least 24 hours because of the time required for the bacteria to travel from the tick midgut to its salivary glands. Prompt removal and detection of ticks is the primary method for reducing infection; however, ~300,000 people are still infected with Lyme disease each year in the US alone.

        The bacteria responsible for causing Lyme disease are members of the genus Borrelia, with 12 of the 36 known Borrelia species causing Lyme disease.  Furthermore, the number of ticks infected with Borrelia bacteria is estimated to be increasing by 2.5% annually.  Routine surveillance uses PCR testing on ticks to determine if they carry Borrelia burgdorferi, which is the most common species found in North America; however, new species have been detected and a shift in strain prevalence due to climate changes and regional restrictions of tick travel is expected to continue occurring. 

      Diagnostics

    • Medical Devices
      • Integrated Neonatal Support with Placental Transfusion and Resuscitation (INSPIRE)

        Integrated Neonatal Support with Placental Transfusion and Resuscitation (INSPIRE)

        Current international guidelines for the management of infants at birth suggest that there be a delay before the umbilical cord is clamped, this may confer benefit by improving cardiovascular function and postnatal adaptation. Studies show that remaining connected to the umbilical cord for one to three minutes after birth reduces the risk of bleeding in the brain by as much as fifty per cent. The standard care for health newborns is to wait at least one minute after birth before cutting the umbilical cord.

      • Pneumothorax Drainage Device

        Pneumothorax Drainage Device

        Spontaneous pneumothorax is a significant global health problem with an estimated incidence of up to two million events per year globally. Air in the chest cavity can sometimes resolve itself but often requires a hospital admission and more importantly, lifesaving urgent medical care. In a military combat setting, about thirteen per cent of penetrating wounds to the thoracic cavity require thoracic intervention including a chest tube, contributing up to thirty per cent of combat deaths.

      • Trans-esophageal Aortic Compression Balloon

        Trans-esophageal Aortic Compression Balloon

        Massive blood loss from severe abdominal or distal limb trauma is challenging to control and necessitates surgical intervention. Current therapies rely on blood replacement products which can be difficult to obtain and may lead to complications for the patient. The trans-esophageal aortic compression balloon works to control blood loss, reducing the need to replace lost blood.

      Medical Devices

    • Therapeutics
      • Novel cyclodextrin-based excipients for drug formulations

        Novel cyclodextrin-based excipients for drug formulations

        Cyclodextrins (CDs) are cyclic oligosaccharides used for the improvement of water-solubility and bioavailability of medicinal products. At least six types are available on the market. This class of excipients can be readily tailored for use in drug formulations.

      • Novel Nucleoside-based Antiprotozoan Drugs

        Novel Nucleoside-based Antiprotozoan Drugs

        Infectious diseases caused by parasites are a serious global health problem with significant rates of morbidity and mortality. Due to the emergence of treatment-resistant strains of many pathogens, there is a clear need for novel approaches to infectious disease treatment.

      • Novel Proteins with Anti-bacterial and Anti-eukaryotic Activity

        Novel Proteins with Anti-bacterial and Anti-eukaryotic Activity

      • Therapeutic Application of AlphaB-cystallin Promotes Recovery from Peripheral Nerve Injury

        Therapeutic Application of AlphaB-cystallin Promotes Recovery from Peripheral Nerve Injury

        Damage to peripheral nerves often lead to dysfunction of hands, arms and legs because nerve fibers do not regrow completely in humans. Despite being a common injury, current treatment options rely on surgical anastomosis or nerve engraftment often leading to non-optimal outcomes. Moreover, adequate time for a surgery is often missed as surgical treatment decisions are made later after an initial diagnosis of the injury. An effective treatment option is needed for peripheral nerve injury as delayed surgical repair can result in only partial nerve regeneration.

        AlphaB-crystallin (HSPB5/CRYAB/αBC) is a small heat shock protein that enhances survival in response to stress by inhibiting protein aggregation, reducing levels of intracellular reactive oxygen species and inhibiting programmed cell death. αBC is constitutively expressed by the peripheral nervous system (PNS) axons and Schwann cells. The inventors discovered that loss of the crystallin impaired conduction velocity as well as motor and sensory functions were likely related to deficits in remyelination. Intravenous injections of recombinant human αBC promoted remyelination and functional recovery in wild-type mice following a sciatic nerve crush injury revealing a therapeutic effect of αBC.

      Therapeutics

    • The Mild Behavioral Impairment Checklist (MBI-C)

      The Mild Behavioral Impairment Checklist (MBI-C)

      The emergence of neuropsychiatric symptoms in older adults may provide an indicator of early neurodegenerative disease and dementia. The syndrome Mild Behavioral Impairment (MBI) describes the relationship between later-life onset of sustained neuropsychiatric symptoms and changes in behavior and personality, and the risk of cognitive decline and dementia. The International Society to Advance Alzheimer’s Research and Treatment - Alzheimer’s Association (ISTAART-AA) diagnostic criteria for MBI were published in Alzheimer's & Dementia (Ismail, et al., 2016).

    Life & Medical Sciences

  • Manufacturing & Industrial Application

    Manufacturing & Industrial Application

  • Other
    • Medical Training Devices
      • Soiled Airway Trainer

        Soiled Airway Trainer

        Approximately twenty-five per cent of pre-hospital trauma cases require airway management by emergency response personnel, and delays in proper airway management are a common cause of preventable death in pre-hospital and emergency settings. If performed improperly, airway management procedures can cause secondary injuries to patients. Training emergency personnel to effectively manage a patient's airway is vital for patient safety and optimal treatment conditions.

      Medical Training Devices

    • Womba Musical Instrument

      Womba Musical Instrument

      Empowering a child's physical and psychological development through in utero movement, artistic expression and parental bonding.

    Other

  • Social & Clinical Innovation

    Social & Clinical Innovation

INNOVATE CALGARY
WEBSITE TERMS OF USE


These Terms of Use (“Terms”) govern your use of the site operated by University Technologies International Inc., and UTI Limited Partnership (hereinafter collectively referred to as “Innovate Calgary”). Anyone who wishes to use this Site must accept these Terms without change. BY ACCESSING THIS SITE, YOU ARE INDICATING YOUR ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND ANY POLICIES INCORPORATED INTO THESE TERMS.

Your use of the Site will be subject to the most current version of the Terms posted on the Site at the time of use and each time you access the Site, you indicate your acceptance and agreement to the current Terms. If there are any changes to these Terms, your continued use of this Site after such changes are implemented constitutes your acknowledgment and acceptance of the changes. Please consult these Terms regularly. IF YOU DO NOT AGREE TO ANY CHANGES TO THESE TERMS, PLEASE IMMEDIATELY DISCONTINUE YOUR USE OF THE SITE.

1.    Access to Site. To access publicly available portions of this Site, no login is required. However, you are still bound by these Terms even without a login. To access other parts or features of the Site, or services that Innovate Calgary has to offer, certain users may be required to provide registration and login details. It is a condition of your use of this Site that all the information that you provide to this Site will be correct, current and complete.

2.    Access to Services. As part of your use of the Site, you may make use of certain application forms to obtain services from Innovate Calgary. The services provided to you by Innovate Calgary may be subject to additional terms and financial terms that will be communicated to you in writing.

3.    Privacy Policy. All of the information about identifiable individuals submitted by users is governed by our Privacy Policy, as may be amended from time to time, which is incorporated into these Terms.  When you agree to these terms, you agree to the Privacy Policy. The Privacy Policy describes Innovate Calgary’s personal information handling policies and practices in detail. Innovate Calgary advises you to check the Privacy Policy on a frequent basis for changes. 

4.    Content.

 (a)    The Site contains text, data, information graphics, photos, logos, icons, trademarks, and other content furnished by Innovate Calgary. You acknowledge that the Site Content is for general information purposes only, and is not intended to constitute specific business advice. 

(b)    The Site also provides a venue for you to search for information, and the Site has additional features permitting you to input, contribute, post or upload information, data, invention disclosures, invention descriptions, personal or organizational descriptions, events, comments, submissions, products, materials, ideas and other content.

 (c)    By inputting, contributing, posting or uploading any User Content, you automatically grant to Innovate Calgary and its successors, assigns and affiliated entities, a perpetual, royalty-free, irrevocable, unrestricted, non-exclusive, worldwide, assignable, sub-licensable, right and license to use, copy, display such User Content for the purposes of assessing the User Content, and providing services to you in respect of such User Content. If Innovate Calgary does not provide services to you, it may retain archived copies of the User Content.

(d)    In respect of User Content that is posted in any events calendar, forum or comments area that is accessible to other users, as the Site may permit, you acknowledge that users may input, contribute, post or upload User Content without endorsement by Innovate Calgary, so you need to conduct your own review of any User Content accessed by you and accept responsibility for use or reliance on such content. User Content may be owned or licensed by other users. 

(e)    In respect of any User Content that you input, contribute, post or upload, you represent and warrant that you have all necessary rights to make such User Content available on the Site, and that you are not violating our acceptable use policies or infringing any third-party rights, or breaching contractual rights by doing so. 

(f)    Users are independent from Innovate Calgary, and Innovate Calgary has no responsibility or liability for or control over users or User Content. Innovate Calgary does not sponsor or endorse users or User Content. Your access and use of any User Content and your dealings with other users is at your own risk.

5.    Acceptable Use: 

You may use this Site for your own personal information or for purposes of applying for or using Innovate Calgary services, or other features as may be available through this Site from time to time. You may not use this Site for any improper purpose except as expressly contemplated and permitted by the Site. The Site may be used only for authorized purposes by users who have agreed to these Terms. You must comply with all applicable federal, provincial and local laws and regulations in your use of the Site. You must also abide by Innovate Calgary acceptable use standards, and any acceptable use policy published by Innovate Calgary from time to time. You may not:

(a)    post, input or upload any User Content that is vulgar, obscene, contains explicit or graphic descriptions or accounts of sexual acts or sexual language of a violent or threatening nature or constitutes child pornography under applicable law;

(b)    threaten bodily harm, destruction of property or otherwise engage in harassment; 

(c)    transmit, post, store, link or distribute any threatening, abusive, harassing, defamatory, libelous, deceptive or fraudulent information or information that is invasive of another's privacy, or infringes another’s rights;

(d)    transmit, post, store, link or distribute material that victimizes, harasses, degrades, threatens to harm or intimidates an individual or group of individuals, including without limitation minors, on the basis of religion, gender, sexual orientation, race, ethnicity, age or disability;

(e)    reverse engineer, decompile or otherwise attempt to decipher any code or any portion of the Site for any purpose;

(f)    aggregate, scrape, harvest or duplicate any portion of our Site, including any personal or contact information, or use such personal or contact information for any secondary marketing purposes or unsolicited mass e-mail, or any purpose inconsistent with the purposes of the Site;

(g)    corrupt, falsify or distort any User Content or Personal Data or upload, post or submit User Content that infringes any copyright, or other intellectual property rights, or offends privacy rights, or otherwise offends the standards set by us from time to time; or

(h)    copy, misuse or duplicate the layout and design of our sites, or the underlying code and database structures, or any of our trade-marks.

6.    Intellectual Property Rights & Confidentiality

The Site Content is owned by Innovate Calgary and its licensors and is protected by copyright and trademark laws and other intellectual property laws of Canada and other nations. Innovate Calgary does not, by these Terms, claim any ownership rights in intellectual property in any User Content submitted through the Site. Where Innovate Calgary requires any interest in your intellectual property as part of the provision of its services, any such assignments or licenses will be subject to separate written terms assented to by both parties. 
Innovate Calgary will maintain confidentiality in any confidential portions of User Content. Not all User Content is to be considered confidential, and Innovate Calgary’s obligations of confidentiality do not extend to any User Content or other information which is:

(a)    Specifically marked as non-confidential;

(b)    Known to Innovate Calgary at the time of disclosure by you;

(c)    Publicly available through no fault of Innovate Calgary;

(d)    Independently developed by Innovate Calgary without regard to the confidential information;

(e)    Required to be disclosed pursuant to any law, regulatory requirement or court order. 

7.    Unsolicited Submissions. The Site does not constitute an invitation for unsolicited submissions by you of your own products, materials, ideas, inventions or projects. You are making any such submissions of your own User Content because of your interest in Innovate Calgary’s service offerings. Innovate Calgary wishes to avoid misunderstandings and disputes when products, materials, ideas, inventions or projects that are in the Innovate Calgary portfolio are, or appear to be, similar to your own User Content. By submitting any such User Content to Innovate Calgary, you acknowledge and agree that: (a) Innovate Calgary has multiple projects and intellectual property assets under development or management, and any one of these projects or assets may contain elements that are, or appear to be, similar or identical to your User Content; (b) any similarity between any User Content and any elements in Innovate Calgary’s portfolio would be purely coincidental; (c) you waive all claims against Innovate Calgary, University Technologies International Inc., UTI Limited Partnership, UTI Business Ventures Inc., UTI Commercial Trust and UTI Venture Management Inc. and their respective directors, officers, affiliates, successors and assigns (collectively, the “Innovate Calgary Parties”) in respect of any such similarity or related intellectual property claims.

8.    Security Acknowledgement. You acknowledge that Innovate Calgary cannot guarantee the security of any information, communicated by email or the internet.  While we implement industry-standard security protocols, the internet, the use of email, and the Site are all subject to security flaws and risks.  You accept those risks by using the Site.

9.    Disclaimer of Warranties/Limitation of Liability. You understand that Innovate Calgary cannot and does not guarantee or warrant that the Site or files available for downloading from the Internet will be free of viruses, worms, trojan horses or other code that may manifest contaminating or destructive properties. You are responsible for implementing sufficient procedures and checkpoints to satisfy your particular requirements for accuracy of data input and output. Innovate Calgary does not assume any responsibility or risk for your use of the Internet. Innovate Calgary does not represent or warrant that the content, the Site, its servers or email sent from the Site are free of viruses or other harmful components.
YOUR USE OF THIS SITE IS AT YOUR OWN RISK. EXCEPT AS MAY OTHERWISE EXPRESSLY BE PROVIDED ON THE SITE, EVERYTHING ON THE SITE, INCLUDING THE CONTENT, IS PROVIDED “AS IS” AND “AS AVAILABLE” WITHOUT REPRESENTATIONS, WARRANTIES, GUARANTEES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED. EXCEPT AS MAY OTHERWISE EXPRESSLY BE PROVIDED ON THE SITE, THE INNOVATE CALGARY PARTIES EXPRESSLY DISCLAIM ALL REPRESENTATIONS, WARRANTIES, GUARANTEES AND CONDITIONS, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, QUIET ENJOYMENT OR NON-INFRINGEMENT OR THOSE ARISING OUT A COURSE OF DEALING OR USAGE OF TRADE.

THE TOTAL LIABILITY OF THE INNOVATE CALGARY PARTIES, WHETHER UNDER THE EXPRESS OR IMPLIED TERMS OF THIS AGREEMENT, IN TORT (INCLUDING NEGLIGENCE OR OTHER DUTY OF CARE) OR AT COMMON LAW, FOR ANY LOSS OR DAMAGE INCLUDING BUT NOT LIMITED TO ANY DATA LOSS OR CORRUPTION, SUFFERED BY YOU OR ANY OF YOUR USERS OR THIRD PARTIES, WHETHER DIRECT, INDIRECT OR SPECIAL, OR ANY OTHER SIMILAR DAMAGE THAT MAY ARISE OR DOES ARISE FROM THE SITE, OR ANY BREACH OF THIS AGREEMENT BY ANY INNOVATE CALGARY PARTIES, IS LIMITED TO THE AMOUNT OF THE FEE (IF ANY) PAID TO INNOVATE CALGARY BY YOU FOR ACCESS TO THE SITE OR THE AMOUNT OF $50 CDN, WHICHEVER IS GREATER.  

10.    Applicable Law. These Terms and any action related thereto or related to the Site and the content will be governed, controlled, interpreted and defined by and under the laws of the Province of Alberta and the federal laws applicable therein. You agree that any action at law or in equity arising out of or relating to these Terms of Use or your use of the Site and the content will be filed only in a court located in Calgary, Alberta, Canada. 

11.    Termination. You acknowledge and agree that these Terms of Use will remain in effect for so long as you use this Site. You agree that this agreement can only be terminated by you once you have stopped using the Site. Innovate Calgary reserves the right to terminate your use of the Site at any time, for any reason, with or without cause, if Innovate Calgary believes that you are violating these Terms in any way. 

12.    General. This Site may contain links to other sites which are not maintained by, or related to, Innovate Calgary. Hyperlinks to such sites are provided solely as a convenience to you and do not imply any endorsement by Innovate Calgary of, any affiliation with or endorsement by the owner of the linked site. Innovate Calgary has no control over such third-party sites. Other terms may apply to you once you access those separate sites. These Terms and any other legal notices, legal terms, policies and guidelines of Innovate Calgary linked to these Terms or otherwise made available to you in connection with the Site or any services available through the Site constitute the entire agreement between you and Innovate Calgary relating to the subject matter hereof. You may not assign, convey, subcontract or delegate your rights, duties or obligations hereunder. Innovate Calgary may assign this agreement in the course of a corporate reorganization, merger or acquisition without prior notice to you. If any provision of the Terms is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavour to give effect to the parties’ intentions as reflected in the provision, and the other provisions of the Terms remain in full force and effect. It is the express will of the parties that this agreement and all related documents be drawn up in English. C'est la volonté expresse des parties que la présente convention ainsi que les documents qui s'y rattachent soient rédigés en anglais.

 
Please contact Innovate Calgary at 3553 31 Street NW, Calgary, AB T2L 2K7 CANADA 

Last updated: Jan. 30, 2018